Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

El.En. Investor Presentation 2016

Mar 16, 2016

4393_cp_2016-03-16_6ab24178-e29a-4234-b045-4c5d6398c320.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

COMPANY PRESENTATION

2015 FINANCIAL RESULTS

Disclaimer

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Summary

  • 1.LASERS AND LASER APPLICATIONS
  • 2.THE GLOBAL LASER MARKET
  • 3.EL.EN. GROUP
  • 4.2015 FINANCIAL RESULTS
  • 5.2016 TARGETS
  • 6.EL.EN. STOCK, MULTIPLES & COMPARABLES

Lasers and Laser Applications

LASER

Light Amplification by Stimulated Emission of Radiation

MEDICALLASER Systems

INDUSTRIALLASER Systems

Medicaland Aest. Applications

Industrial lasers applications

2015 Hot Products

Monna Lisa Touch

Cyber TM 200

Discovery Pico

Motus AX

The Global Laser Market

The MEDICAL Laser Market

\$
l
b
l
k
f
d
l
l
b
d
h
h
(
l
l
)
i
i
i
G
2
0
1
9
t
t
o
a
m
a
r
e
o
r
m
e
c
a
a
s
e
r
s
y
e
n
u
s
e
r
o
u
g
m
o
n
s
,
2
0
1
3		 2
0
1
4		 C
A
G
%
R
2
0
1
4
2
0
1
9
-
7
5
8		 8
1
3		 1
2
1
9		 %
8
4
,
8
9
5		 0
2
1
4		 2
0
9
7		 %
1
5
4
,
2
0
9		 2
4
4		 6
2
3		 2
0
%
7
,
9
9		 1
1
5		 2
4
7		 1
6
%
5
,
1
9
6
1		 2
1
9
5		 4
1
8
5		 1
3
8
%
,
2
0
1
9

Global market for medical lasers by region, through 2019 (\$ millions)

k
M
S
t
t
a
r
e
e
g
m
e
n		 2
0
1
3		 2
0
1
4		 2
0
1
9		 %
C
A
G
R
2
0
1
4
2
0
1
9
-
d
d
U
S
C
a
n
a
n
a
a		 9
0
2		 1
0
0
8		 1
8
7
0		 1
3
2
%
,
E
u
r
o
p
e		 5
7
9		 6
4
7		 1
2
0
8		 %
1
3
3
,
f
i
i
i
A
P
s
a
a
c
c		 3
5
2		 3
9
9		 8
4
9		 %
1
6
3
,
h
O
t
e
r		 2
8
1		 1
4
1		 2
8
5		 2
8
%
1
,
l
T
t
o
a		 9
6
1
1		 2
9
1
5		 8
4
1
5		 3
8
%
1
,

The INDUSTRIAL Laser Market

Global market and forecast for high power laser systems by application (by value)

l
B
V
a
e
y
u		 l
b
l
G
M
o
a
a		 k
(
l
i
E
U
R
M
t
r
e		 (
)
C
A
G
R
%
2
0
1
3		 2
0
1
6		 2
0
2
0		 2
0
1
3
2
0
1
6
-		 2
0
1
6
2
0
2
0
-
C
i
t
t
n
u
g		 2
4
0
8		 3
0
1
4		 3
9
6
5		 7
8
,		 7
1
,
l
d
d
i
i
W
B
e
n
g
a
n
r
a
n
g
z		 1
2
4
9		 1
6
0
5		 2
2
3
1		 8
7
,		 8
6
,
f
d
h
S
O
t
t
t
t
u
r
a
c
e
r
e
a
m
e
n
a
n
e
r		 5
0		 6
3		 8
6		 8
3
,		 8
1
,
l
T
t
o
a		 3
7
0
7		 4
6
8
2		 6
2
8
2		 8
1
,		 7
6
,

El.En. Group

Group Overview

High –Tech laser photonics Group

Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications

Know-how based on 35 years stratification of multidisciplinary experience

2015: Consolidated Revenues of €218 mln, up 21% YoY

965 employees

Global positioning

Strategic Strengths

Multidisciplinary and multifacility R&D activity: sources, systems, applications

Industrial

Combine High tech laser source development with flexible production facilities in high growth areas

Medical

Technological and clinical innovation improving performance andbroadening the application scope of our laser systems

  • Maximize market penetration by multi brand approach
  • Open new market segments by developing innovative applications
  • Leverage worldwide distribution with multi brand approach

Consolidated Revenuesand EBIT

R&D Activity

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser- tissue interaction

Broadening Mona Lisa Touch Clinical studiesNew Pico second laser platform Clinical studies on cutaneous ulcers Painless laser hair removalPatents developmentIncreased power of RF laser sourcesInnovative applications for mid power laser systems

2015 Financial Results

ConsolidatedP&L

/
E
0
0
0
u
r
o		 /
/
3
2
1
1
1
4		 /
/
3
2
1
1
1
5		 %
V
a
r.
d
d
i
t
n
a
e
u
u
R
e
v
e
n
u
e
s		 1
8
0
0
0
9		 1
0
0
0
%
,		 2
1
7
6
7
0		 1
0
0
0
%
,		 2
0
9
%
,
i
G
r
o
s
s
m
a
r
g
n		 8
8
9
1
4		 %
4
5
5
,		 9
6
3
8
1		 %
4
4
2
,		 %
1
7
7
,
E
B
I
T
D
A		 1
7
9
6
3		 0
0
%
1
,		 2
5
6
6
6		 8
%
1
1
,		 2
9
%
4
,
E
B
I
T
(
*
)		 1
5
3
0
1		 %
8
5
,		 2
1
4
9
9		 %
9
9
,		 %
4
0
5
,
P
I
t
(


)
r
e
a
n
c
o
m
e
x		 2
0
9
4
4		 3
6
%
1
,		 2
3
1
1
3		 0
6
%
1
,		 3
%
5
-
,
i
N
t
(


*
)
e
n
c
o
m
e		 1
6
5
2
0		 9
2
%
,		 1
4
3
7
1		 6
6
%
,		 1
3
0
%
-
,
h
N
I
t
e
n
c
o
m
e
p
e
r
s
a
r
e		 3
4
2
,		 2
9
8
,

(*) 2014 Non recurring: +1,5 mln of euros. 2014 EBIT% w/o non recurring: 7,7% and var% 15/14 adj.: +55%(**) 2014 Total one time and non recurring: +9,0mln of euros on pretax income and var% 15/14 adj.: +65%(***) 2014 Total one time and non recurring: +8 mln of euros on net income and var% 15/14 adj.: +68%

Balance sheet

/
0
0
0
E
r
o
u		 /
/
3
1
1
2
1
4		 /
/
3
1
1
2
1
5
d
d
i
t
u
n
a
u
e		 %
V
a
r.
l
T
t
t
t
o
a
n
o
n
r
r
e
n
a
s
s
e
s
c
u		 6
1
7
7
5		 9
6
6
7
7		 8
%
5
k
i
i
l
N
W
C
t
t
e
o
r
n
g
a
p
a		 4
9
5
0
1		 5
9
8
6
1		 %
2
1
f
l
i
i
i
i
N
t
t
e
n
a
n
c
a
p
o
s
o
n		 4
7
1
1
6		 2
9
8
1
5		 %
3
7
-
l
b
l
i
i
i
i
L
t
t
o
n
g
e
r
m
a
e
s		 7
8
5
6		 7
9
0
4		 %
1
i
N
E
t
t
e
q
u
y		 0
3
6
1
5
5		 9
3
9
1
7
5		 9
%
1
i
l
l
d
N
t
t
e
c
a
p
a
e
m
p
o
y
e		 1
0
3
4
2
0		 1
4
9
7
2
4		 %
4
5
k
l
l
i
i
N
W
C
t
t
e
o
r
n
g
a
p
a
o
n
s
a
e
s		 2
7
%		 2
8
%
O
C
R
E
/
(
l
l
d
)
i
E
B
I
T
N
t
t
e
c
a
p
a
e
m
p
o
y
e		 %
1
5		 %
1
4
C
a
p
e
x		 8
4
7
7		 8
2
3
4

2016Targets

2016 Targets

Increase Sales by >= 5%

Match 2015's EBIT

El.En. Stock, Multiples & Comparables

Euro

El.En. Multiples

k
h
l
d
's
h
*
S
i
E
t
t
o
c
o
e
r
q
u
y
p
e
r
s
a
r
e		 3
5
/
k
l
d
i
j.
P
B
V
A
r
c
e
o
o
a
u
e		 1,
1
8
/
(
)
V
I
8
%
I
E
E
B
T
5
E
B
T		 6,
3
5
/
(
)
l
l
E
V
S
8
5
%
S
a
e
s
a
e
s		 0,
6
4
l.
k
E
E
M
C
t
n
a
r
e
a
p		 1
9
7,
8
@
€
4
1,
0
0
f
l
i
i
i
i
N
t
t
e
n
a
n
c
a
p
o
s
o
n		 /
/
2
9,
8
@
3
2
1
1
1
5
/
i
i
l
i
l
F
t
t
t
n
a
n
c
a
n
e
s
m
e
n
s
m
e
r
m
v		 /
/
@
1
0,
6
3
1
1
2
1
5
k
l
f
h
1,
0
C
M
t
a
r
e
v
a
u
e
o
m
m
y
n
o
s
u
r
e
s
a
r
e
s		 \$
3
8,
0
@
2,
2
6
4
/
(
)
d
E
U
1,
1
1
u
r
o
s
=
l
i
E
V
t
n
e
r
p
r
s
e
a
u
e		 1
1
9,
3
k
h
l
d
's
f
i
i
i
i
S
E
t
t
t
t
o
c
o
e
r
q
u
y
n
e
o
m
n
o
r
e
s,
*
(
)
h
h
k
l
i
C
t
t
t
w
y
n
o
s
u
r
e
s
a
r
e
s
a
m
a
r
e
v
a
u
e		 1
6
7,
5

El.En. Comparables

D
3
1
2
0
1
5
t ,
e
c
s		 ic
Pr
e		 Re
ve
nu
e		 %
Va
r.
Re
ve
nu
e		 E
B
I
T		 %
E
B
I
T		 C
M
K.
a
p.		 E
V		 /
le
S
E
V
a
s		 /
E
V
E
B
I
T		 /
k
P
Bo
o
lu
Va
e
/
d
l
h
i
A
i
M
t
t
e
c
a
e
s
e
c
S
y
n
e
r
o
n		 \$
8,
1
6		 \$
2
7
7.
8
4
9		 9
%		 \$
(
)
6.
4
5
9		 -2
%		 \$
3
0
6.
7
1
0		 \$
2
2
0.
0
5
4		 0,
7
9		 n.
a.		 1,
4
7
l
i
Z
t
e
q		 \$
2
3,
2
3		 \$
2
6
5
5.
4
1		 6
%
4		 \$
3.
6
9
4		 %
1		 \$
9
2
0.
0
4
4		 \$
8
6
7
1.
7
1		 3,
4
1		 2
3
9
9
5,		 0
7,
4
C
t
u
e
r
a		 \$
1
2,
6
6		 \$
9
4.
7
6
1		 2
1
%		 \$
(
)
4.
5
2
1		 -5
%		 \$
1
6
9.
0
2
0		 \$
1
2
0.
6
1
3		 1,
2
7		 n.
a.		 3,
3
8
i
l
B
o
a
s
e		 \$
1,
2
1		 \$
4
8.
4
7
5		 2
%		 \$
(
)
1
9.
9
1
5		 -4
1
%		 \$
6
9.
3
1
0		 \$
5
7.
5
7
0		 1,
1
9		 n.
a.		 2,
7
8
C
n
o
s
r
e
y
u		 \$
4
2,
2
6		 \$
3
3
9.
4
6
2		 1
6
%		 \$
2
6.
3
2
1		 8
%		 \$
1.
0
2
0.
0
0
0		 \$
8
9
4.
1
1
4		 2,
6
3		 3
3,
9
7		 2,
5
2
d
i
l
I
t
n
u
s
r
a
h
I
P
G
P
i
C
t
o
o
n
s
o.
c		 \$
9
0,
9
4		 \$
9
0
1.
2
6
5		 1
7
%		 \$
3
4
2.
0
4
3		 3
8
%		 \$
4.
9
1
0.
0
0
0		 \$
4.
2
2
0.
8
8
4		 4,
6
8		 1
2,
3
4		 3,
8
9
f
i
i
R
S
o
n-
n
a
r		 \$
2
3,
4
8		 \$
5
0
9.
7
1
7		 -4
%		 \$
5
6.
9
7
9		 1
1
%		 \$
6
8
3.
3
2
0		 \$
5
1
2.
5
9
0		 1,
0
1		 9,
0
0		 1,
2
4
l.
(
)
E
E
1
n.		 €
4
1,
0
0		 €
2
1
7.
6
7
0		 2
1
%		 €
2
1.
4
9
9		 1
0
%		 €
1
9
7.
7
9
9		 €
1
1
9.
3
2
1		 0,
6
4		 6,
5
3		 1,
1
8

(1) EV and multiplies as for previous slide

El.En. SPA

Enrico ROMAGNOLI Investor Relations Managertel. +39 055-8826807E-mail: [email protected]

POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI Financial CommunicationTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]

POLYTEMS HIR SRL

Silvia MARONGIUPress officeTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]

More from El.En.

Regulatory Filings 2026
May 18
Regulatory Filings 2026
May 18
Regulatory Filings 2026
May 18
Investor Presentation 2026
May 18
Report Publication Announcement 2026
May 18
Report Publication Announcement 2026
May 18
Report Publication Announcement 2026
May 15
Interim / Quarterly Report 2026
May 15
Interim / Quarterly Report 2026
May 15
Interim / Quarterly Report 2026
May 15
View all filings →